萨库比特里尔/瓦尔沙坦对心力衰竭的血管内皮作用,减少排气部分:随机对照试验
Matthias P Nägele1, Thomas Haider1, Leonie Kreysing1
1Cardiology, University Heart Center Zurich, University Hospital Zurich, Zurich, Switzerland.
JACC. Advances
|November 28, 2024
概括
与单独使用瓦尔沙坦相比,萨库比特里尔/瓦尔沙坦在心力衰竭患者中没有改善内皮功能或动脉硬性. 然而,它确实降低了血压,并显示了改善视网膜静脉功能的趋势.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 萨库比比特里尔/瓦尔萨坦增强心力衰竭与减少喷射率 (HFrEF) 的结果的确切机制仍未完全阐明.
- 了解这些机制对于优化HFrEF管理中的治疗策略至关重要.
研究的目的:
- 调查萨库比特里尔/瓦尔萨坦对内皮功能,视网膜微血管功能和HFrEF患者动脉硬性的影响.
- 为了在受控临床试验环境中比较萨库比特里尔/瓦尔萨坦与瓦尔萨坦单一治疗的效果.
主要方法:
- 一项双盲对照试验,涉及79名稳定的HFrEF患者 (NYHAII-IV类),随机分配给接受sacubitril/valsartan或单独的瓦尔萨坦3个月.
- 主要终点:流媒体血管扩张 (FMD). 二级终点:视网膜动脉和静脉的闪诱导扩张 (FIDv),视网膜动脉静脉比率,脉冲波速度和增强指数.
主要成果:
- 在初级结局 (口病) 中,在萨库比特里尔/瓦尔萨坦和瓦尔萨坦组之间没有发现显著差异 (6.6%±3.9%对比6.7%±2.8%,P=0.53).
- 二级结局,包括视网膜微血管功能和动脉硬性标记,也没有显示群体之间的显著差异.
- 萨库比特里尔/瓦尔沙坦显著降低了缩血压 (-6.5 mm Hg,P=0.04) 并显示出较低FIDv (P=0.04) 的趋势.
结论:
- 与HFrEF患者的瓦尔萨坦单疗相比,萨库比特里尔/瓦尔萨坦并没有改善内皮功能,视网膜微血管功能或动脉硬性.
- 该药物有效降低了血压,并表明对视网膜静脉功能有潜在的益处,这需要进一步调查其血管效应.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
590
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
590
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
479
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
479
01:25Antihypertensive Drugs: Direct Renin Inhibitors
493
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
493